2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial

References

• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan 2021. Arnhem, the Netherlands, EAU Guidelines Office.Available from: https://uroweb.org/guideline/prostate-cancer/.
   Google Scholar
• Schaeffer E, Srinivas S, Antonarakis ES National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®): Prostate Cancer. Version 2.2021. [cited, et al. 2021. Aug 24];Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
   Google Scholar
• Lowrance WT, Breau RH, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol. 2021;205(1):22–29.
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245.
   PubMed Web of Science ®Google Scholar
• Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, PROSTY study group, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14(2):117–124.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI): Division of Cancer Treatment & Diagnosis (DCTD). Common Toxicity Criteria (CTC). Version 2.0 1999. [cited 2021 Dec 8]; Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf.
   Google Scholar
• Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the international society of geriatric oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116–136.
   PubMed Web of Science ®Google Scholar
• Parker C, Castro E, Fizazi K, ESMO Guidelines Committee. Electronic address: [email protected], et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2020;31(9):1119–1134.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2018;73(2):178–211.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, for the CONSORT group CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.
   PubMed Web of Science ®Google Scholar
• Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50(6):920–928.
   PubMed Web of Science ®Google Scholar
• FACT-P: Functional Assessment of Cancer Therapy – Prostate. For patients with Prostate cancer. [cited 2021. May 15];Available from: https://www.facit.org/measures/FACT-P.
   Google Scholar
• Yount S, Cella D, Banik D, et al. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT advanced prostate symptom index (FAPSI). Health Qual Life Outcomes. 2003;1(1):69.
   PubMedGoogle Scholar
• FAPSI: Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 8 Item Version [cited 2021. Dec 9];Available from: https://www.facit.org/measures/FAPSI.
   Google Scholar
• Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11(3):570–579.
   PubMed Web of Science ®Google Scholar
• Delgado DA, Lambert BS, Boutris N, et al. Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. JAAOS Glob Res Rev. 2018;2(3):e088.
   Google Scholar
• Fairclough DL, Cella DF. Functional assessment of cancer therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996;5(3):321–329.
   PubMed Web of Science ®Google Scholar
• Li G, Taljaard M, Van Den Heuvel ER, et al. An introduction to multiplicity issues in clinical trials: the what, why, when and how. Int J Epidemiol. 2017;46(2):746–755.
   PubMed Web of Science ®Google Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
   Web of Science ®Google Scholar
• Cella D, Nichol MB, Eton D, et al. Estimating clinically meaningful changes for the functional assessment of cancer therapy—prostate: Results from a clinical trial of patients with metastatic Hormone-Refractory prostate cancer. Value Health. 2009;12(1):124–129.
   PubMed Web of Science ®Google Scholar
• King MT, Cella D, Osoba D, et al. Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Relat Outcome Meas. 2010;1:119–126.
   PubMedGoogle Scholar
• King MT, Stockler MR, Cella DF, et al. Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. J Clin Epidemiol. 2010;63(3):270–281.
   PubMed Web of Science ®Google Scholar
• Frahm Olsen M, Bjerre E, Hansen MD, et al. Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol. 2018;101:87–106.e2.
   PubMed Web of Science ®Google Scholar
• Thiery-Vuillemin A, Fizazi K, Sartor O, et al. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. ESMO Open. 2021;6(2):100089.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hozaeel W, Tauchert FK, et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015;26(6):1244–1248.
   PubMed Web of Science ®Google Scholar
• Gelman A, Carlin J. Beyond power calculations: Assessing type S (sign) and type M (magnitude) errors. Perspect Psychol Sci. 2014;9(6):641–651.
   PubMedGoogle Scholar
• Wang C, Hall CB. Correction of bias from non-random missing longitudinal data using auxiliary information. Stat Med. 2010;29(6):671–679.
   PubMed Web of Science ®Google Scholar
• Ibrahim JG, Molenberghs G. Missing data methods in longitudinal studies: a review. Test (Madr). 2009;18(1):1–43.
   PubMed Web of Science ®Google Scholar
• Fielding S, Ogbuagu A, Sivasubramaniam S, et al. Reporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade? Qual Life Res. 2016;25(12):2977–2983.
   PubMed Web of Science ®Google Scholar
• Bell ML, Kenward MG, Fairclough DL, et al. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ. 2013;346(1):e8668–e8668.
   PubMed Web of Science ®Google Scholar
• Kumle L, Võ MLH, Draschkow D. Estimating power in (generalized) linear mixed models: an open introduction and tutorial in R. Behav Res Methods. 2021;53:2528–2543.
   PubMed Web of Science ®Google Scholar
• Cella D, Ivanescu C, Holmstrom S, et al. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol. 2015;26(1):179–185.
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. Statistics notes: the cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080.
   PubMed Web of Science ®Google Scholar
• Mabikwa OV, Greenwood DC, Baxter PD, et al. Assessing the reporting of categorised quantitative variables in observational epidemiological studies. BMC Health Serv Res. 2017;17(1):201.
   PubMed Web of Science ®Google Scholar
• Neve OM, van Benthem PPG, Stiggelbout AM, et al. Response rate of patient reported outcomes: the delivery method matters. BMC Med Res Methodol. 2021;21(1):9.
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Bullinger M, Aaronson N, Clinical Significance Consensus Meeting Group, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res. 2005;14(2):285–295.
   PubMed Web of Science ®Google Scholar
• Frost MH, Bonomi AE, Ferrans CE, Clinical Significance Consensus Meeting Group, et al. Patient, clinician, and population perspectives on determining the clinical significance of quality-of-Life scores. Mayo Clin Proc. 2002;77(5):488–494.
   PubMed Web of Science ®Google Scholar
• Haslam A, Herrera-Perez D, Gill J, et al. Patient experience captured by quality-of-Life measurement in oncology clinical trials. JAMA Netw Open. 2020;3(3):e200363–e200363.
   Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–154.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385(12):1091–1103.
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102.
   PubMed Web of Science ®Google Scholar
• National Instititures of Health (NIH). The National Center for Advancing Translational Sciences (NCATS). Inxight Drugs Database. Docetaxel [cited 2022. May 27]; https://drugs.ncats.io/drug/15H5577CQD
   Google Scholar